Support scientific researchers in assigned key pharma/biotech/academic accounts by providing oligonucleotide/gene synthesis services, cloning, plasmid prep, protein expression and custom peptides. Promote synthetic biology services in the area of vector design, gene expression in bacteria, insect, yeast and various mammalian cell lines. Provide scientific technical support in the areas of custom antibodies, screening of single domain antibody libraries of naïve and immunized probes for protein functionality research. Successfully exceeded forecast by delivering desired genes in various plasmids, AAV and Lentiviral and cas9-sgRNA-crispr vectors.

• Exceeded forecast by contracting Service lab and identifying high throughput cytokine screening research in the assigned territory, primarily California. Worked with SAMs and AMs to identify miRNA and cytokine multiplex labs and provided FirePlex Platform virtual presentations. Worked with FAS for Flow Cytometer and High Content Imager set up as well as service and commercial operations.

• Worked with life science, chemistry suppliers and researchers to position VWR as a distributor partner for academics in San Diego. Responsible for selling centrifuges, plate readers, microscopes, chemicals and reagents to all University of California researchers and teaching labs.

• Successfully increased sales by 38% over annual quota in 2018, selling biochemicals, cellular/molecular biology/gene editing tools along with chemistry building blocks used for scientific pharmaceutical research in San Diego specifically Pfizer, Genomics Novartis Research, Johnson and Johnson, and Eli Lilly, Pacira and NittoDenko.• Worked with distributor-VWR & ThermoFisher and sold direct Calbiochem/Novagen, EMD Chemicals and Sigma /Aldrich brands in assigned accounts.EMD Chemicals/EMD Millipore Account Manager III 2007-2016 • Awarded top sales performance in 2010 – Highest percent sales increase over previous year in Americas.• Exceeded sales forecast by average of 10% for both EMD and Millipore bioscience product portfolios supporting Academic and Biotech/Pharmaceutical accounts in San Diego, New Mexico and Arizona.• Prepared semi-annual tactical sales plans for exceeding forecast in each of the top 5 accounts.• Worked with both VWR and Fisher to distribute EMD Millipore brands in each account managing salesforce CRM. Provided quarterly territory analysis report using excel.

• Developed account plan for University of California, San Diego and Irvine to convert molecular and cellular biology research customers to Invitrogen brands. • Exceeded corporate sales forecast by 15%.• Worked with both UC distribution channels to maximize profit margin and ROI.• Participated in UC/Invitrogen strategic meetings in product positioning and technical partnerships.

• Developed financial valuation models identifying the epidemiology, market segment pricing and expenses needed for profit/loss statements to value each product opportunity in autoimmune, oncology and GI areas.• Conducted secondary market research using IMS and NDC data and presented the analysis of risk and competitive situations in the revenue valuation model to business development management.• Designed primary market research questionnaire with vendors and conducted interviews with thought leaders in related disease areas. Worked with R&D and Finance in identifying potential opportunities.• Built a gastroenterology database and identified therapeutics drugs that fit Prometheus diagnostics test area.

• Successfully increased sales by 12% and profit of Fisher Chemical and Bioscience brands used in pharmaceutical and biotechnology companies and academic research labs in Southern California.• Provided technical sales presentations to directors of laboratories differentiating Fisher Chemical brands from competitors. Recommended strategic purchasing proposals for bundling and incentives.• Organized academic technical seminars at UC Irvine to position and promote each brand.• Provided regional competitive analysis including pricing and positioning used by Fisher Marketing.

• Received Ligand’s Outstanding Achievement Award in 2001.• Completed Ligand’s strategic plan in conjunction with Commercial Operations, Research, Project Management, Finance and Legal teams, analyzing and coordinating technical and market intelligence. • Designed financial models for drugs under development and marketed drugs considering different tactical scenarios. Monitored intellectual property information for Ligand’s Corporate Partner Products in the areas of osteoporosis, endocrinology, metabolism, inflammation and oncology. Provided risk adjusted net present value for drugs in development and clinical phase including FDA approved label for each disease market. • Presented verbal and written presentations of net present value of in-license opportunities and possible out-license products. Examples include The Liposome Company’s delivery system, Glaxo Dermatology products, Inex’s OncoTCS and Immunex’s Leukine. Performed commercial assessment of the Androgen agonist program prior to partnering it out to TAP Pharmaceuticals.

• Developed new accounts and supported existing customers in the combinatorial chemistry market in the United States. Exceeded sales forecast by 50%.• Built Lotus Notes database organizing technical calls based on customers’ needs. Database was utilized for synthesizing 35 new products for combinatorial chemistry research market.• Negotiated new product licensing and pricing for high-throughput synthesis of peptides, and solid and solution phase resins. Examples include Monsanto, Chugai, and Roche.

• Lead a technical sales team and exceeded sales forecast for three consecutive years. Trained distributors in US (VWR, IMS) to position products based on customers’ needs and win sales of capital equipment used for cell transfection and hybridoma production. Provided technical support to manufacturers’ representatives in Europe and Japan.• Responsible for competitive analysis, pricing and revenue forecasting for electroporation and electrofusion equipment and consumables. Prepared profit and loss financial statements under various scenarios.• Successfully introduced six new types of equipment by collaborating with several beta-sites to test new products and generate protocols used for transfection of cells lines with plasmid constructs.• Organized Access database to track published references that used electroporation as a method of transfection and electrofusion to form hybridomas for antibody production. Published several manuscripts on the subject available on the web.